Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AEMD Aethlon Medical

Post-Mkt 05-20 17:04:42 EDT

2.07

+0.02

+0.98%

盘后2.04

-0.03-1.45%

16:50 EDT

High2.10	Low1.98	Vol38.75K
Open1.99	D1 Closing2.05	Amplitude5.85%
Mkt Cap3.25M	Tradable Cap3.06M	Total Shares1.57M
T/O79.61K	T/O Rate2.62%	Tradable Shares1.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AEMD","market":"US","secType":"STK","nameCN":"Aethlon Medical","latestPrice":2.07,"timestamp":1779307200000,"preClose":2.05,"halted":0,"volume":38747,"hourTrading":{"tag":"盘后","latestPrice":2.04,"preClose":2.07,"latestTime":"16:50 EDT","volume":40,"amount":82.19,"timestamp":1779310208809,"change":-0.03,"changeRate":-0.014493,"amplitude":0.014493},"delay":0,"changeRate":0.009756097560975618,"floatShares":1478200,"shares":1569100,"eps":-48.46,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"05-20 17:04:42 EDT","open":1.9888,"high":2.1,"low":1.98,"amount":79614.6039365,"amplitude":0.058537,"askPrice":2.12,"askSize":500,"bidPrice":1.96,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-48.46,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779321600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.05,"preHourTrading":{"tag":"盘前","latestPrice":2.05,"preClose":2.05,"latestTime":"08:44 EDT","volume":545,"amount":1126.9756885000002,"timestamp":1779281062856,"change":0,"changeRate":0,"amplitude":0.02439},"postHourTrading":{"tag":"盘后","latestPrice":2.04,"preClose":2.07,"latestTime":"16:50 EDT","volume":40,"amount":82.19,"timestamp":1779310208809,"change":-0.03,"changeRate":-0.014493,"amplitude":0.014493},"volumeRatio":0.210373,"impliedVol":3.8125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AEMD","defaultTab":"news","newsList":[{"id":"2622871447","title":"Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622871447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622871447?lang=en_us&edition=fundamental","pubTime":"2026-03-28 01:09","pubTimestamp":1774631364,"startTime":"0","endTime":"0","summary":"Aethlon Medical outlined its Hemopurifier platform, an extracorporeal blood filtration device designed to capture enveloped viruses and extracellular vesicles using an affinity resin.The company reported 173 treatments in 44 patients and said its clinical safety database shows a favorable safety profile.Aethlon Medical said it has two FDA Breakthrough Device designations covering advanced or metastatic cancer and life-threatening viral infections with no approved therapies.In its Australian oncology trial, the company said cohorts 1 and 2 are complete and cohort 3 is open for enrollment.Key financial highlights cited cash of about USD 7.0 million and about 1.6 million shares outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8dGMcR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4082","BK4568","AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064201","title":"Aethlon Medical advances to final cohort in AEMD-2022-06 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064201?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:11","pubTimestamp":1774354290,"startTime":"0","endTime":"0","summary":"Aethlon Medical (AEMD) announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial AEMD-2022-06 has completed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aethlon-medical-advances-to-final-cohort-in-aemd-2022-06-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aethlon-medical-advances-to-final-cohort-in-aemd-2022-06-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","AEMD","BK4568","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621646470","title":"Aethlon Medical opens final cohort in Hemopurifier oncology trial after DSMB review finds no safety concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2621646470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621646470?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353896,"startTime":"0","endTime":"0","summary":"Aethlon Medical said its independent Data Safety Monitoring Board reviewed safety data from the second cohort of clinical trial AEMD-2022-06 and recommended advancing to the third and final cohort.The study is evaluating the safety, feasibility, and dose-finding of the Hemopurifier device in patients with solid tumors receiving pembrolizumab or nivolumab.In Cohort 2, participants received 2 Hemopurifier treatments over 1 week, and the company reported no serious adverse events or dose-limiting toxicities related to the device or treatment to date.Cohort 3 enrollment is open, with participants planned to receive 3 treatments over 1 week at 3 clinical sites in Australia.The company said the study is designed to enroll about 9 to 18 patients and that a final data set and clinical study report will be prepared in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3K82sw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4082","BK4583","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064536","title":"Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive Dsmb Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064536?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353875,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AEMD","BK4082","BK4568","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064522","title":"Aethlon Medical Inc: Dsmb Also Stated That \"No Safety Concerns Were Noted With Hemopurifier Device/Procedure\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064522?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353875,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0MQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4082","AEMD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620478238","title":"Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620478238","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620478238?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:52","pubTimestamp":1773755549,"startTime":"0","endTime":"0","summary":"An update from Aethlon Medical ( ($AEMD) ) is now available. Aethlon Medical, Inc., a medical technology company, reported that it has 1,569,110 sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-completes-pre-funded-warrant-exercises-simplifying-equity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-completes-pre-funded-warrant-exercises-simplifying-equity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4215","BK4588","EQR","BK4583","BK4568","BK4585","AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420879","title":"Aethlon Medical says all pre-funded warrants have been exercised","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420879?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:15","pubTimestamp":1773753346,"startTime":"0","endTime":"0","summary":"Aethlon Medical said recent exercises of certain pre-funded warrants increased its common shares outstanding to 1,569,110 as of the close of business on March 16, 2026. The company said all previously outstanding pre-funded warrants have been exercised.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbP7NTf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4082","BK4583","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618310401","title":"Aethlon Medical Engages Maxim Group to Review Strategic Alternatives, Including Potential Partnerships, Mergers and Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2618310401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618310401?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:08","pubTimestamp":1773317308,"startTime":"0","endTime":"0","summary":"Aethlon Medical Engages Maxim Group to Review Strategic Alternatives, Including Potential Partnerships, Mergers and Acquisitions. Aethlon Medical said it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC as exclusive financial advisor to review potential transactions. The review will consider options such as partnerships, mergers, acquisitions and other alternatives, with no set timeline and no assurance that a transaction will occur. The company also plans to submit safety data from the second cohort of its Australian oncology trial to an independent Data Safety Monitoring Board for review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL3PQRQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4082","BK4583","AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131288","title":"Aethlon Medical Engages Maxim Group Llc to Evaluate Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131288","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131288?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:01","pubTimestamp":1773316860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA1SS7FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AEMD","BK4568","BK4082","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617638257","title":"**Aethlon Medical CEO Jim Frakes to present at Life Sciences Investor Forum**","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638257","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617638257?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:35","pubTimestamp":1772804134,"startTime":"0","endTime":"0","summary":"**Aethlon Medical CEO Jim Frakes to present at Life Sciences Investor Forum**               Aethlon Medical, Inc. (Nasdaq: AEMD) will present live at the Life Sciences Investor Forum on March 12, 2026","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL6rFjNs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","BK4568","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4588","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","BK4583","AEMD","NDAQ","LU2095319765.USD","LU2210149790.SGD","BK4082","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613782883","title":"Aethlon Medical to Present at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782883","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782883?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:03","pubTimestamp":1771851803,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8cqLbg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4583","BK4568","AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611905488","title":"Aethlon Medical Posts Q3 Results, Highlights Hemopurifier Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2611905488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611905488?lang=en_us&edition=fundamental","pubTime":"2026-02-13 06:04","pubTimestamp":1770933883,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Aethlon Medical ( ($AEMD) ). On February 12, 2026, Aethlon Medical reported results for its fiscal third quarte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-posts-q3-results-highlights-hemopurifier-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-posts-q3-results-highlights-hemopurifier-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4583","BK4568","AEMD","BK4097","PRGS","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611690855","title":"Aethlon Medical Q3 operating expenses up 13.6% yr/yr","url":"https://stock-news.laohu8.com/highlight/detail?id=2611690855","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611690855?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:27","pubTimestamp":1770931654,"startTime":"0","endTime":"0","summary":"Aethlon Medical Q3 operating expenses up 13.6% yr/yrOverviewMedical therapeutic firm's fiscal Q3 operating expenses rose 13.6% yr/yrOperating expenses for nine months declined 26.9% yr/yrCompany advan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","AEMD","BK4082","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611970482","title":"AEMD Q3 operating expenses rise 13.6% to USD 2.06 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970482","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611970482?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:16","pubTimestamp":1770931016,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. reported its financial results for the third quarter  ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology develo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL2Y7Csx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4082","AEMD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611704229","title":"Aethlon Medical Q3 EPS $(2.45) Beats $(2.57) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2611704229","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611704229?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:16","pubTimestamp":1770930966,"startTime":"0","endTime":"0","summary":"Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(2.45) per share which beat the analyst consensus estimate of $(2.57) by 4.67 percent. This is a 135.58 percent decrease over losses of $(1.04) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50596433/aethlon-medical-q3-eps-2-45-beats-2-57-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aethlon Medical Q3 EPS $(2.45) Beats $(2.57) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611970472","title":"Press Release: Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611970472?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:15","pubTimestamp":1770930900,"startTime":"0","endTime":"0","summary":"Clinical and research programs continue to advance, supported by year-to-date cost efficiencies. SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc.  , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.-- Maintained Nasdaq Listing: Continued compliance with Nasdaq listing. requirements, with all prior compliance matters remaining resolved.--  Clinical Progress: Cohort 2 of the Australian oncology trial is actively. -- Scientific Advancement: Continued advancement of the Company's. COVID data published on bioRxiv and submitted for peer review, supporting. the Hemopurifier's potential as a multi-indication therapeutic approach. compatibility with a simplified blood treatment system to support broader. in lower year-to-date operating expenses compared to prior year.The Aethlon R&","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","HP","R","BK4583","BK4568","BK4082","MTA","BK4022","AEMD","BK4188","BK4092"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608364627","title":"Aethlon Medical Inc. veröffentlicht demnächst neue Quartalszahlen und lädt zur Investorenkonferenz ein","url":"https://stock-news.laohu8.com/highlight/detail?id=2608364627","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608364627?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:02","pubTimestamp":1770210148,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL4JxXBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","AEMD","BK4082","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606224451","title":"Aethlon Medical Amends Warrants to Allow Immediate Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224451?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:48","pubTimestamp":1769467691,"startTime":"0","endTime":"0","summary":"The latest update is out from Aethlon Medical ( ($AEMD) ). On January 22, 2026, Aethlon Medical, Inc. and an institutional investor amended a Decem...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-amends-warrants-to-allow-immediate-exercise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-amends-warrants-to-allow-immediate-exercise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","AEMD","BK4568","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604191679","title":"Aethlon Medical Inc. Announces Date for Upcoming Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2604191679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604191679?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:17","pubTimestamp":1768598220,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. has announced that its Annual Meeting of Stockholders will be held on February 19, 2026. The meeting will address the election of director nominees and other matters that may properly come before the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLcfNyKg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4082","AEMD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593144880","title":"BRIEF-Aethlon Medical Inc Files For Common Stock Offering Of $15 Million, SEC Filing Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2593144880","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593144880?lang=en_us&edition=fundamental","pubTime":"2025-12-24 04:34","pubTimestamp":1766522074,"startTime":"0","endTime":"0","summary":"BRIEF-Aethlon Medical Inc Files For Common Stock Offering Of $15 Million, SEC Filing ShowsDec 23  - Aethlon Medical Inc AEMD.O:AETHLON MEDICAL INC: FILES FOR COMMON STOCK OFFERING OF $15 MILLION - SEC FILINGSource text: [ID:n0001683168-25-009335]Further company coverage: AEMD.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0AS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4568","BK4583","BK4082"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aethlonmedical.com","stockEarnings":[{"period":"1week","weight":-0.0639},{"period":"1month","weight":-0.1239},{"period":"3month","weight":-0.0191},{"period":"6month","weight":-0.4258},{"period":"1year","weight":-0.9382},{"period":"ytd","weight":-0.2599}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.2335},{"period":"ytd","weight":0.076}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.360101},{"month":2,"riseRate":0.090909,"avgChangeRate":-0.164148},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.10297},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.093808},{"month":5,"riseRate":0.272727,"avgChangeRate":-0.121559},{"month":6,"riseRate":0.8,"avgChangeRate":0.195518},{"month":7,"riseRate":0.2,"avgChangeRate":-0.085564},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.064693},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.084082},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.111246},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.001468},{"month":12,"riseRate":0.454545,"avgChangeRate":0.017294}],"exchange":"NASDAQ","name":"Aethlon Medical","nameEN":"Aethlon Medical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aethlon Medical,AEMD,Aethlon Medical股票,Aethlon Medical股票老虎,Aethlon Medical股票老虎国际,Aethlon Medical行情,Aethlon Medical股票行情,Aethlon Medical股价,Aethlon Medical股市,Aethlon Medical股票价格,Aethlon Medical股票交易,Aethlon Medical股票购买,Aethlon Medical股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}